secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-04-11T23:59:59+00:00
Accession:  0001437749-25-011724
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia initiates patient enrollment at Emory University for Phase III heart failure trial
--------------------------------------------------------------------------------

- Emory University School of Medicine is now enrolling patients with ischemic heart failure in BioCardia's pivotal Phase III CardiAMP HF II trial.
- Dr. Arshed Quyyumi, Professor of Medicine at Emory, will serve as principal investigator for the autologous cell therapy study.
- Trial compares CardiAMP therapy to placebo; target enrollment completion in 2027 based on prior positive results presented at ACC 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925011724/0001437749-25-011724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925011724/bcda20250411_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-011724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer